Labeling “Highlights” To Depend On Data In Relation To Clinical Setting
Information to be included in the new Highlights of Prescribing Information section of professional labeling will be determined by the clinical setting in which the drug is used, FDA said
You may also be interested in...
Risk Communication Advisory Committee suggests that adding the agency imprimatur to REMS materials may help distinguish it from promotional mail and ensure providers read the communications.
In run-up to FDA's meeting on the internet and social media, PhRMA makes its pitch to restore branded sponsored search engine results.
FDA's standards for an "established" pharmacologic class are that the agency has determined the class is both scientifically valid and clinically meaningful, according to a draft guidance released May 15